Latest news with #AorticValve
Time of India
18 hours ago
- Health
- Time of India
Docs save life with rare heart valve procedure
New Delhi: A 72-year-old woman battling breathlessness, chest pain and severe fatigue - 14 years after undergoing major heart surgery - was given a new lease on life through a rare and risky intervention performed at Apollo Hospitals . Back then, she survived acute aortic dissection with a complex surgery that replaced her damaged aortic valve and root with a tissue valve. Over the years, that valve narrowed dangerously, demanding urgent replacement. Normally this could be managed through a minimally invasive Transcatheter Aortic Valve Implantation (TAVI) via the femoral artery in the leg. However, her situation was far from routine - a chronic Type B aortic dissection left her aorta with two channels, a "true" and a "false" lumen, the latter being larger. This made reaching the heart with catheters extremely risky. Open-heart surgery was ruled out due to the high danger posed by her age, frailty and the residual dissection. Faced with these obstacles, a multidisciplinary team from Apollo's Heart Valve and Aortic Program - led by Dr. Gautam Naik and Dr. Niranjan Hiremath - devised a plan for a rare and complex trans-femoral Valve-in-Valve TAVI procedure . Such cases have been reported only in isolated instances worldwide. After meticulous planning and advanced imaging guidance, the 3.5-hour procedure was performed entirely through the femoral artery. A 23 mm Navitor Vision (Abbott) transcatheter heart valve was successfully implanted, restoring healthy blood flow. The patient recovered well and was discharged in stable condition on the fifth day. A minor new false lumen detected after the procedure was managed conservatively with strict blood pressure control. "In complex heart disease, success often depends on finding safe, innovative solutions tailored to the patient," said Dr. Naik.
Time of India
a day ago
- Health
- Time of India
Docs save life with rare heart valve procedure
New Delhi: A 72-year-old woman battling breathlessness, chest pain and severe fatigue — 14 years after undergoing major heart surgery — was given a new lease on life through a rare and risky intervention performed at Apollo Hospitals. Back then, she survived acute aortic dissection with a complex surgery that replaced her damaged aortic valve and root with a tissue valve. Over the years, that valve narrowed dangerously, demanding urgent replacement. Normally this could be managed through a minimally invasive Transcatheter Aortic Valve Implantation (TAVI) via the femoral artery in the leg. However, her situation was far from routine — a chronic Type B aortic dissection left her aorta with two channels, a "true" and a "false" lumen, the latter being larger. This made reaching the heart with catheters extremely risky. Open-heart surgery was ruled out due to the high danger posed by her age, frailty and the residual dissection. You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi | Gold Rates Today in Delhi | Silver Rates Today in Delhi Faced with these obstacles, a multidisciplinary team from Apollo's Heart Valve and Aortic Program — led by Dr. Gautam Naik and Dr. Niranjan Hiremath — devised a plan for a rare and complex trans-femoral Valve-in-Valve TAVI procedure. Such cases have been reported only in isolated instances worldwide. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Could This NEW Collagen Blend Finally Reduce Your Cellulite? Vitauthority Learn More Undo After meticulous planning and advanced imaging guidance, the 3.5-hour procedure was performed entirely through the femoral artery. A 23 mm Navitor Vision (Abbott) transcatheter heart valve was successfully implanted, restoring healthy blood flow. The patient recovered well and was discharged in stable condition on the fifth day. A minor new false lumen detected after the procedure was managed conservatively with strict blood pressure control. "In complex heart disease, success often depends on finding safe, innovative solutions tailored to the patient," said Dr. Naik. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
The Wire
7 days ago
- Health
- The Wire
Manipal Hospitals Kolkata completes 50 successful TAVR cases
KOLKATA, India, Aug. 12, 2025 /PRNewswire/ -- Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital), Kolkata is thrilled to announce the completion of 50 successful Transcatheter Aortic Valve Replacement (TAVR) cases, establishing the facility as a regional market leader in structural cardiac procedures in Eastern India. TAVR is a minimally invasive approach of treating patients with severe aortic stenosis who are at high or prohibitive risk for traditional open-heart surgery. This is more than just a number, it demonstrates a patient's faith, cutting-edge infrastructure, the collaboration of the interdisciplinary heart team, and the unwavering commitment to giving patients a second chance at life. TAVR procedures are now well established and worldwide more than 120,000 patients underwent TAVR in 50 countries. In India, as of now, 5000 procedures have been performed over the last 10 years. In Eastern India, the highest number of TAVR procedures has been performed in Manipal Hospitals. In recognizing this achievement, Dr. Dilip Kumar,Director Cath Lab, Senior Interventional Cardiologist, Device and Structural Heart Expert, Manipal Hospital - EM Bypass, opined, "TAVR is a cardiac care milestone that has transformed the treatment of valve dysfunction in complex instances, particularly in the elderly and high-risk patients. Achieving the 50-case milestone without complications demonstrates not only our team's expertise, but also the patient-centred ecosystem we have established here at the units of Manipal Hospital in Kolkata. Catheter-based valve replacement is becoming the wave of the future in cardiac intervention, and we are proud to be at the forefront, giving world-class outcomes right here in Eastern India." Dr. Arindam Pande, Senior Consultant, Department of Cardiology and Consultant Interventional Cardiologist, Manipal Hospital - EM Bypass shared, "With TAVR, we can provide a life-saving option to patients who previously had very little to choose from. In contrast to conventional surgeries, this one bypasses the opening of the chest and minimizes risks of anaesthesia. Patients usually go home in a day or two, and such a recovery is nothing less than a revolution. This milestone of 50 cases is a testament to the hospital's progressive attitude towards heart care." Manipal Hospital is committed to harness the latest technology and clinical expertise to change lives. The team continues to strive for greater access to TAVR and providing the optimal recovery and quality of life to structural heart disease patients. About Manipal Hospitals: As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multi-specialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500+ beds and a talented pool of 5,600+ doctors and an employee strength of over 18,600. Manipal Hospitals provide comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals are NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys. Logo: (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.). PTI This is an auto-published feed from PTI with no editorial input from The Wire. This article went live on August twelfth, two thousand twenty five, at twenty-two minutes past four in the afternoon.
Business Standard
7 days ago
- Health
- Business Standard
Manipal Hospitals Kolkata completes 50 successful TAVR cases
PRNewswire Kolkata (West Bengal) [India], August 12: Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital), Kolkata is thrilled to announce the completion of 50 successful Transcatheter Aortic Valve Replacement (TAVR) cases, establishing the facility as a regional market leader in structural cardiac procedures in Eastern India. TAVR is a minimally invasive approach of treating patients with severe aortic stenosis who are at high or prohibitive risk for traditional open-heart surgery. This is more than just a number, it demonstrates a patient's faith, cutting-edge infrastructure, the collaboration of the interdisciplinary heart team, and the unwavering commitment to giving patients a second chance at life. TAVR procedures are now well established and worldwide more than 120,000 patients underwent TAVR in 50 countries. In India, as of now, 5000 procedures have been performed over the last 10 years. In Eastern India, the highest number of TAVR procedures has been performed in Manipal Hospitals. In recognizing this achievement, Dr. Dilip Kumar,Director Cath Lab, Senior Interventional Cardiologist, Device and Structural Heart Expert, Manipal Hospital - EM Bypass, opined, "TAVR is a cardiac care milestone that has transformed the treatment of valve dysfunction in complex instances, particularly in the elderly and high-risk patients. Achieving the 50-case milestone without complications demonstrates not only our team's expertise, but also the patient-centred ecosystem we have established here at the units of Manipal Hospital in Kolkata. Catheter-based valve replacement is becoming the wave of the future in cardiac intervention, and we are proud to be at the forefront, giving world-class outcomes right here in Eastern India." Dr. Arindam Pande, Senior Consultant, Department of Cardiology and Consultant Interventional Cardiologist, Manipal Hospital - EM Bypass shared, "With TAVR, we can provide a life-saving option to patients who previously had very little to choose from. In contrast to conventional surgeries, this one bypasses the opening of the chest and minimizes risks of anaesthesia. Patients usually go home in a day or two, and such a recovery is nothing less than a revolution. This milestone of 50 cases is a testament to the hospital's progressive attitude towards heart care." Manipal Hospital is committed to harness the latest technology and clinical expertise to change lives. The team continues to strive for greater access to TAVR and providing the optimal recovery and quality of life to structural heart disease patients. About Manipal Hospitals: As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multi-specialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500+ beds and a talented pool of 5,600+ doctors and an employee strength of over 18,600. Manipal Hospitals provide comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals are NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.
Yahoo
24-07-2025
- Business
- Yahoo
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics
Edwards Lifesciences (EW) reported $1.53 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 6.1%. EPS of $0.67 for the same period compares to $0.70 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $1.49 billion, representing a surprise of +2.85%. The company delivered an EPS surprise of +8.06%, with the consensus EPS estimate being $0.62. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Europe: $378.2 million versus $353.07 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change. Net Sales- Outside of the United States: $642.5 million compared to the $621.76 million average estimate based on two analysts. The reported number represents a change of +12.9% year over year. Net Sales- United States: $889.7 million versus $865.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change. Net Sales- Japan: $95.3 million compared to the $105.11 million average estimate based on two analysts. The reported number represents a change of +9% year over year. Net Sales- Rest of World: $169 million versus the two-analyst average estimate of $163.59 million. The reported number represents a year-over-year change of +15.7%. Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies: $134.5 million versus $129.87 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +62.1% change. Net Sales by Product Group- Surgical Structural Heart: $266.8 million versus the seven-analyst average estimate of $259.33 million. The reported number represents a year-over-year change of +1%. Net Sales by Product Group- Transcatheter Aortic Valve Replacement: $1.13 billion versus $1.1 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change. View all Key Company Metrics for Edwards Lifesciences here>>> Shares of Edwards Lifesciences have returned -0.1% over the past month versus the Zacks S&P 500 composite's +5.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
